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Increased incidence of neurological complications
in patients receiving an allogenic bone marrow
transplantation from alternative donors
C de Brabander, J Cornelissen, P A E Sillevis Smitt, Ch J Vecht, M J van den Bent
Abstract
Objective—To compare the frequency and
type of neurological complications after
bone marrow transplantation (BMT) with
an HLA identical unrelated donor or a
mismatched related donor (alternative
donors) to the neurological complications
after matched sibling BMT for standard
and high risk leukaemia or myelodysplas-
tic syndromes.
Methods—Retrospective analysis of con-
secutively treated patients with (a) BMT
from alternative donors (n=39), (b)
treated with matched sibling BMT for
standard risk leukaemia, myelodysplastic
syndromes, or aplastic anaemia (n=53),
and (c) treated with matched sibling BMT
for high risk leukaemia, myelodysplastic
syndromes, or aplastic anaemia (n=49).
Results—A total of 72 neurological com-
plications were found. Most of these
occurred within the first 6 months after
transplant. Thirty six patients developed a
severe neurological complication: 17 Al-
ternative donor patients (44%) by contrast
with six standard risk patients (11%) and
13 high risk patients (27%; p<0.005). The
most frequent complication was a meta-
bolic encephalopathy occurring in 18% of
patients. Most of the encephalopathies
were caused by either the transplant
procedure, cyclosporin, systemic infec-
tions, microangiopathic thrombopathy, or
by complications induced by graft versus
host disease. Infections of the CNS devel-
oped in 9% of patients, cerebrovascular
lesions in 3%.
Conclusions—Severe neurological com-
plications are more frequent after BMT
from alternative donors. This is mainly
due to increased treatment related mor-
bidity and to more profound immunosup-
pression after BMT from alternative
donors.
(J Neurol Neurosurg Psychiatry 2000;68:36–40)
Keywords: bone marrow transplantation; neurological
complications; alternative donors
High dose chemotherapy with total body
irradiation followed by either autologous or
allogenic bone marrow transplantation (BMT)
is an eVective treatment for various haemato-
logical disorders. Unfortunately, an HLA iden-
tical sibling donor is only available for a few
patients due to matching criteria. Some of
these patients can be treated with allogenic
BMT from alternative donors: HLA mis-
matched sibling donors and HLA-identical
unrelated donors. However, allogeneic BMT
from alternative donors is associated with con-
siderable morbidity and treatment related
mortality. Risk factors for treatment related
complications and mortality include older age,
type, and risk status of underlying disease,
degree of HLA matching, donor type, and
comorbidity factors of the patient. Major com-
plications which contribute to treatment re-
lated mortality are opportunistic infections,
graft versus host disease, interstitial pneumoni-
tis, and veno-occlusive disease.1–3
Neurological complications are an impor-
tant cause of treatment related morbidity and
may contribute to it. The few studies that con-
sidered these complications are diYcult to
compare due to diVerences in patient selection,
criteria for neurological complications, or type
of BMT. Two often quoted reports on
neurological complications of BMT are post-
mortem studies.4 5 Another study only consid-
ered neurological complications of BMT in
childhood.6 Studies on consecutively treated
adults are rare.7–9 These studies suggest that the
incidence and type of neurological complica-
tions are related to the type of transplantation
(allogenous v autologous) and to the type of
disease. No study has specifically investigated
frequency and type of these complications in
BMT from alternative donors. We investigated
retrospectively the incidence and outcome of
neurological complications in these patients,
and compared these to the neurological
complications occuring in cohorts of standard
and high risk BMT patients treated with an
allograft from HLA identical sibling donors.
Methods
The records of all patients who received an
allogenic BMT from an alternative donor or
treated with a BMT from an HLA identical
sibling for high risk leukaemia or myelodysplas-
tic syndromes at the Daniel den Hoed Cancer
Center, Rotterdam were reviewed. A group of
50 consecutively treated patients with standard
risk leukaemia and all patients with standard
risk aplastic anaemia treated in the same period
served as a control group. The patients were
classified into these three categories according
to donor type and risk status of underlying dis-
ease:
(1) Alternative donors—Patients who re-
ceived an allogenic graft from either an HLA
matched unrelated donor or an HLA mis-
matched related donor.
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(2) Standard risk patients—patients who
received an allogenic graft from an HLA iden-
tical sibling donor in first chronic phase
chronic myeloid leukaemia, or for untreated
aplastic anaemia.
(3) All other patients with leukaemia (with
more advanced disease status), patients with
myelodysplastic syndromes, and patients with
previously treated aplastic anaemia receiving a
BMT from an HLA identical sibling donor
were considered high risk patients.
The medical records of all patients were
reviewed and the data evaluated were: age, sex,
primary disease, conditioning regimen, graft
versus host disease prophylaxis, and the occur-
rence, nature, and outcome of neurological
complications. The registration of neurological
complications began with the start of the con-
ditioning regimen; for this study complications
occurring at the time of disease relapse or
thereafter were not considered. The complica-
tions were divided into four categories: infec-
tions of the CNS, encephalopathic disorders
(including drug induced seizures), cerebrovas-
cular complications and “other” complica-
tions. By definition, (a) all syndromes with
decreased level of consciousness due to sys-
temic organ dysfunction without structural
abnormalities on CT orMRI, (b) drug induced
seizures, and (c) posterior leukoencephalopa-
thy syndromes10 were considered encephalopa-
thies. Less severe drug induced CNS complica-
tions without decreased levels of consciousness
such as extrapyramidal syndromes were reck-
oned among the “other” complications. For
this study, cutaneous Herpes zoster infections
were not considered. All cases of cyclosporin
induced tremor are mentioned separately.
Complications were graded according to the
NCIC common toxicity criteria (CTC), re-
vised version (1994). Grade 3 (severe) and
grade 4 (life threatening) complications were
considered as “serious” complications. To
allow for suYcient follow up and documenta-
tion of neurological complications the interval
between the time of transplant and this survey
was at least 1 year. For comparison between
groups a two tailed ÷2 test with Yates’
correction was used, p<0.05 was considered
significant.
Results
Between 1983 and 1995, 39 patients received
an allogeneic bone marrow graft from an alter-
native donor, 49 BMT patients were consid-
ered high risk patients; the standard risk group
consisted of 53 patients. Patient characteristics
are summarised in table 1. At the time of
evaluation, 14 alternative donor patients
(36%), 20 high risk patients (41%), and 28
standard risk patients (53%) were alive. Table 2
summarises all neurological complications of
the diVerent groups. Fifty nine patients (42%)
had a total of 72 neurological complications,
most of which occurred within the first 6
months after the transplantation procedure.
Table 3 shows the number of serious complica-
tions. Seventeen alternative donor patients
(44%) compared with six standard risk patients
(11%) and 13 high risk patients (27%;
p<0.005) had a neurological complication that
met the criteria for severe or life threatening.
Four alternative donors and two high risk
patients developed two serious complications.
In univariate analysis, no relation was found
between the occurrence of serious complica-
tions and sex (p=0.93) or age (<40 years v >40
years; p=0.98). Logistic regression analysis
showed no relation between diagnosis and the
occurrence of serious complications (p=0.19),
correction for BMT group did not alter this
conclusion.
Twenty six patients (18%) developed a
metabolic encephalopathy: 10 alternative
donor patients (26%), 11 high risk patients
(21%), and five standard risk patients (9%). In
one third of cases the encephalopathy was part
of a terminal event. After exclusion of terminal
Table 1 Patient and treatment characteristics of the three treatment groups
Alternative donor High risk Standard risk
No of patients 39 49 53
Mean age (range) 31 (14–48) 41 (15–56) 36 (16–56)
Sex:
Male 23 27 32
Female 16 20 20
Primary diagnosis:
ALL 8 6 17
AML 10 17 20
MDS/MPS 7 10 0
CML 9 14 13
Aplastic anaemia 5 2 3
GVHD Prophylaxis
T cell depletion + CyA 37 37 50
MTX + CyA 3 10 6
T cell depletion 2 1
CyA 1
Conditioning:
Cyclo-TBI 4 8 35
Cyclo-TBI + Ara-C 22 21 17
Cyclo-TBI + VP-16 10 12 0
Cyclo, busulphan 3 8 1
ATG 31 0 0
ALL=acute lymphoblastic leukaemia; AML=acute myeloid leukaemia; CML=chronic myeloid
leukaemia; MDS/MPS=myelodysplastic−/myeloproliferative syndrome; BM=bone marrow;
GVHD: graft versus host disease; MTX=methotrexate; CyA=cyclosporine A;
Cyclo=cyclophosphamide; ATG=conditioning regimen also included antithymocyte globulins;
TBI=total body irradiation.
Table 2 Neurological complications found in the three treatment groups
Complication
Alternative
donor (n=39)
High risk
(n=49)
Standard
risk (n=53)
Total
(n=141)
CNS infection 6 4 2 12
Encephalopathy 12* 11 5 28
Vascular complications 3 1 0 4
Other 8 7 13 28
Total 29 23 20 72
*Two patients had two episodes with an encephalopathy.
Table 3 Number of serious complications per patient in the three treatment groups
One serious
complication
Two serious
complications
Total No of serious
complications Total No of patients
Alternative donor (n=39) 13 4 21 17 (p=0.0010)*
High risk leukaemia (n=49) 11 2 15 13 (p=0.089)*
Standard risk leukaemia ( n=53) 6 0 6 6
*p Values of the comparison with the standard risk group.
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encephalopathies, seven alternative donor pa-
tients, seven high risk patients, and two stand-
ard risk patients developed an encephalopathy.
Three alternative donor patients and one high
risk patient developed severe cyclosporin en-
cephalopathies, with visual disturbances,
hypertension, and seizures. Two of them had
cyclosporin concentrations within the thera-
peutic range, all recovered after stopping CyA,
or dose reduction. One patient of the alterna-
tive donor group and three high risk patients
developed a metabolic encephalopathy as a
direct result of the BMT conditioning regimen.
Two of these patients (both with high risk leu-
kaemia) developed seizures after the adminis-
tration of busulfan, despite prophylactic anti-
epileptic treatment.11 The encephalopathy was
related to systemic infections in seven patients,
in seven to multiorgan dysfunction or failure,
and in three to severe systemic graft versus host
disease. In three patients it was caused by a
thrombotic microangiopathy, which proved
fatal in two. The other patient developed a
posterior leukoencephalopathy syndrome with
cortical blindness which was reversible on
plasmapheresis.
Twelve patients developed a CNS infection,
six in the alternative donor group, four in the
high risk group, and two in the standard risk
group. Three cases of a cerebral toxoplasmosis
infection were seen, all in alternative donor
patients. One of these patients died of a rapidly
progressive systemic infection, the other two
recovered after treatment. Three patients
developed a bacterial meningitis, one of whom
died. They were caused by Pseudomonas aerogi-
nosa, Hemophilus influenzae, and Pneumococcus
respectively, and occurred on day 116, day 180,
and day 317. Two patients with multiple
intracerebral abscesses died from other compli-
cations (respiratory failure, severe graft versus
host disease) before a causative agent could be
identified; necropsy was refused in both cases.
One case of EBV encephalitis with full recovery
after treatment with ganciclovir has been previ-
ously reported.12 No causative micro-organism
could be established in three patients with
probable viral meningoencephalitis, both were
treated with broad spectrum antibiotics and
acyclovir. The outcome was fatal in one but the
others made a full recovery. Three alternative
donor patients and one high risk patient devel-
oped cerebrovascular complications. One pa-
tient had multiple haemorrhagic infarcts dur-
ing fatal multiple organ failure. One patient
had seizures due to a haemorrhage in the right
occipital lobe, one patient developed a cortical
vein thrombosis, and one patient had transient
ischaemic attacks for which no cause was
established.
Various less severe complications were
noted. Nine patients had less serious but
potentially dangerous cyclosporin toxicity, con-
sisting of varying combinations of headache,
visual disturbances, an increased blood pres-
sure, and tremor. One patient had a cy-
closporin induced extrapyramidal syndrome;
he recovered completely after discontinuation.
Seven cases of other drug induced extrapy-
ramidal disorders (all caused by antiemetics)
were found. All but one recovered with biperi-
den or a dose reduction of the oVending drug.
Six patients had mild distal sensory motor
neuropathy after BMT. Three patients had
Bell’s palsy, one patient had a mild peroneal
neuropathy, and one patient developed Lher-
mitte’s sign. A cyclosporin related tremor was
seen in 16 patients (11%).
Discussion
This study provides a detailed survey of neuro-
logical complications after BMT in 39 con-
secutively treated patients with grafts from
alternative donors and of 49 high risk patients
treated with a BMT from an HLA identical
sibling. These were compared to the neurologi-
cal complications found in a group of 53 con-
secutively treated standard risk patients. Al-
though the type of neurological complications
did not diVer between the three groups of
patients, severe complications were more fre-
quent after BMT from alternative donors
compared with BMT for standard risk patients
(p<0.005). Some caution in the interpretation
of the results of this retrospective survey is
warranted, as this study is not a randomised or
matched comparison. Such a comparison is
virtually impossible, due to the many diVer-
ences between patients for disease and previous
treatments.
The increased incidence of neurological
complications in alternative donor patients
reflects the higher general treatment related
morbidity and mortality associated with BMT
using alternative donors for BMT for high risk
disease.1 13 An important cause for the in-
creased morbidity in alternative donor recipi-
ents is the increased susceptibility for oppor-
tunistic infections compared with HLA
matched sibling BMT.14 15 The use of antithy-
mocyte globulins in alternative donor BMT for
prevention of graft rejection is a major
diVerence in conditioning regimen between the
treatment groups, which further impairs im-
mune reconstitution after BMT. Immune
reconstitution is also more impaired in patients
receiving a graft which is not fully HLA
matched.16 The incidence of severe neurologi-
cal complications seems slightly higher in high
risk patients.Most of the high risk patients have
undergone several lines of chemotherapy be-
fore the BMT. This increased intensity of pre-
treatment may account for the marginal
increase of severe neurological complications.
Others found a significant impact of CNS
complications on survival.9 Apart from the
CNS infections the neurological complications
did not contribute to the treatment related
mortality in our patients. The prognosis of
encephalopathies was mainly determined by
the underlying cause, if this was reversible a
good neurological recovery was the rule. The
neurological complications, however, did cause
considerable morbidity, even if they were less
severe.
As in other series, the most frequent neuro-
logical complications in our patients were
metabolic encephalopathies. They were found
in 9% of standard risk patients, but in no less
than 26% of patients with alternative donors
38 de Brabander, Cornelissen, Smitt, et al
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and in 21% of the high risk patients. In other
series on allogenic BMT for both standard and
high risk leukaemia, 5%-14% of patients
developed encephalopathies and seizures.6 8 9 A
study on autologous BMT in Hodgkin’s
disease reported metabolic encephalopathies in
27% of patients in the first 6 weeks after BMT,
most of which were secondary to opportunistic
lung infections and respiratory failure.7 How-
ever, any comparison with other studies is dif-
ficult as the reported incidence of neurological
complications is also dependent on the defini-
tion of such complications. We only took those
neurological complications into account which
were subject to further neurological investiga-
tion, and disregarded patients with, for exam-
ple, terminal hepatic failure and encephalopa-
thy in whom treatment had already been
discontinued.We also disregarded neurological
complications at the time of tumour relapse or
thereafter. Other sources for variation of
incidence of neurological complications may
be attributed to diVerences in patient selection
and management of BMT (for example, the
use of T cell depleted transplants). It is also
often diYcult to identify the exact cause of
encephalopathy after BMT. Many patients
have multiple complications at the same
time—for example, sepsis with organ dysfunc-
tion, and are treated simultaneously with neu-
rotoxic drugs such as cyclosporin.
The causes of metabolic encephalopathy in
our patients included systemic infections,
treatment related organ failure including graft
versus host disease, and side eVects of cy-
closporin. Cyclosporin A (CyA) plays a central
part in prevention and treatment of acute graft
versus host disease. It may cause various
neurological side eVects, such as headache,
tremor, seizures, paraparesis, cerebellar symp-
toms, somnolence, and a parkinsonian
syndrome17–22 Many of these symptoms are a
manifestation of the posterior leukoencepha-
lopathy syndrome, characterised by an increase
in blood pressure, headache, visual distur-
bances (such as cortical blindness), and
seizures. Brain CT and MRI usually show
white matter changes, predominantly in the
occipital lobes.10 Neurotoxicity induced by
CyA has been associated with hypomagnesae-
mia, hypercholesterolaemia, hyperlipidaemia,
and concurrent high dose steroid therapy.20 22–25
Four of our patients had a full blown posterior
leukoencephalopathy syndrome, eight other
patients developed only mild signs and symp-
toms of CyA encephalopathy. One patient had
an extrapyramidal syndrome which proved
reversible on withdrawal of CyA. A postural
tremor is the most frequent neurological com-
plication of CyA, in this group it was noted in
12% of patients.
Infections of the CNS are the second most
important source of neurological complica-
tions after BMT. Eight per cent of our patients
developed CNS infections: 15% of all alterna-
tive donor patients, 8% of high risk patients
and 4% of standard risk patients. In series on
adult BMT recipients, two studies on autolo-
gous BMT did not report CNS infections, and
CNS infections were reported in 1%-8% of
patients after allogenic BMT.7–9 26 In this series,
all CNS toxoplasmosis occurred in alternative
donor patients. Other BMT series reported a
1%-2% CNS toxoplasmosis rate.6 8 27 28 The
high rate of CNS infections in our alternative
donor BMT recipients may be explained by the
more profound immunosuppression in these
patients after the use of ATG and the more
profound T cell depletion for prevention of
graft rejection
Similar to our findings, in most studies
cerebrovascular complications (usually haem-
orrhagic) are present in 2%-4% of
patients.8 26 29 Cerebral infarctions after BMT
are associated with non-bacterial thrombotic
endocarditis, but we found no evidence for this
in our patient with recurrent transient ischae-
mic attacks.4 5 30
Three patients in this series developed a
Bell’s palsy. A peripheral facial nerve dysfunc-
tion in patients with a haematological malig-
nancy suggests leptomeningeal metastasis, but
all three patients recovered without treatment.
Recent investigations have suggested that
infections with HSV-1 are the major cause of
Bell’s palsy.31 To the best of our knowledge,
Bell’s palsy has not been reported in BMT
recipients, nor is it more frequent in other
immunocompromised conditions.
In conclusion, Alternative donor patients are
more prone to develop severe neurological
complications than standard risk patients.High
risk patients have a neurological complication
rate in between those two groups. Encepha-
lopathies and CNS infections account for most
of the severe complications. Most likely, the
increased incidence of neurological complica-
tions in alternative donor patients is due to the
more profound and more prolonged immuno-
suppression resulting in an increased suscepti-
bility for opportunistic infections after alterna-
tive donor BMT. Although the neurological
complications add to the increased morbidity
in alternative donor patients, the prognosis of
these complications depends on the underlying
cause, in only a few patients the neurological
complication itself is the cause of a fatal
outcome.
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